24 results on '"Borba, Eduardo F."'
Search Results
2. Influenza A/H1N1 vaccination of patients with SLE: can antimalarial drugs restore diminished response under immunosuppressive therapy?
- Author
-
Borba, Eduardo F., Saad, Carla G. S., Pasoto, Sandra G., Calich, Ana L. G., Aikawa, Nadia E., Ribeiro, Ana C. M., Moraes, Julio C. B., Leon, Elaine P., Costa, Luciana P., Guedes, Lissiane K. N., Silva, Clovis A. A., Goncalves, Celio R., Fuller, Ricardo, Oliveira, Suzimara A., Ishida, Maria A., Precioso, Alexander R., and Bonfa, Eloisa
- Subjects
- *
ANTIMALARIALS , *H1N1 influenza , *ACADEMIC medical centers , *ANTIRHEUMATIC agents , *BLOOD testing , *CLINICAL trials , *CONFIDENCE intervals , *FISHER exact test , *IMMUNIZATION , *IMMUNOSUPPRESSION , *HEALTH outcome assessment , *SYSTEMIC lupus erythematosus , *T-test (Statistics) , *EQUIPMENT & supplies , *TREATMENT effectiveness , *CASE-control method , *PREVENTION , *THERAPEUTICS - Abstract
Objective. To assess the efficacy and safety of pandemic 2009 influenza A (H1N1) in SLE under different therapeutic regimens.Methods. A total of 555 SLE patients and 170 healthy controls were vaccinated with a single dose of a non-adjuvanted preparation. According to current therapy, patients were initially classified as SLE No Therapy (n = 75) and SLE with Therapy (n = 480). Subsequent evaluations included groups under monotherapy: chloroquine (CQ) (n = 105), prednisone (PRED) ≥20 mg (n = 76), immunosuppressor (IS) (n = 95) and those with a combination of these drugs. Anti-H1N1 titres and seroconversion (SC) rate were evaluated at entry and 21 days post-vaccination.Results. The SLE with Therapy group had lower SC compared with healthy controls (59.0 vs 80.0%; P < 0.0001), whereas the SLE No Therapy group had equivalent SC (72 vs 80.0%; P = 0.18) compared with healthy controls. Further comparison revealed that the SC of SLE No Therapy (72%) was similar to the CQ group (69.5%; P = 0.75), but it was significantly reduced in PRED ≥20 mg (53.9%; P = 0.028), IS (55.7%; P = 0.035) and PRED ≥20 mg + IS (45.4%; P = 0.038). The concomitant use of CQ in each of these later regimens was associated with SC responses comparable with SLE No Therapy group (72%): PRED ≥20 mg + CQ (71.4%; P = 1.00), IS + CQ (65.2%; P = 0.54) and PRED ≥20 mg + IS + CQ (57.4%; P = 0.09).Conclusion. Pandemic influenza A H1N1/2009 vaccine response is diminished in SLE under immunosuppressive therapy and antimalarials seems to restore this immunogenicity.Trial registration. www.clinicaltrials.gov, NCT01151644. [ABSTRACT FROM PUBLISHER]
- Published
- 2012
- Full Text
- View/download PDF
3. Prevalence of depressive and anxiety disorders in systemic lupus erythematosus and their association with anti-ribosomal P antibodies
- Author
-
Nery, Fabiano G., Borba, Eduardo F., Viana, Vilma S.T., Hatch, John P., Soares, Jair C., Bonfá, Eloísa, and Neto, Francisco Lotufo
- Subjects
- *
SKIN diseases , *DERMATOLOGY , *BEHCET'S disease , *BLISTERS - Abstract
Abstract: Objective: To estimate the prevalence of psychiatric disorders in patients with systemic lupus erythematosus (SLE) and explore their association with anti-ribosomal P (anti-P) antibodies. Methods: Seventy-one consecutive female SLE patients without neurological manifestations were evaluated for psychiatric disorders using the Structured Clinical Interview for DSM-IV (SCID). Anti-P antibodies were measured by enzyme-linked immunosorbent assay (ELISA)/immunoblot analysis. Results: The mean age of subjects was 34.8 years (SD: 10.1 years), and the mean duration of SLE was 9.8 years (SD: 6.5 years). The 30-day prevalences of psychiatric disorders were: mood disorders 26.8%, anxiety disorders 46.5%, adjustment disorders 8.4%, alcohol abuse 1.4%, and somatoform disorder 1.4%. The lifetime prevalences of psychiatric disorders were: mood disorders 69%, anxiety disorders 52.1%, alcohol abuse 1.4%, and somatoform disorder 1.4%. Subjects with and without psychiatric manifestations did not differ regarding SLE clinical and laboratorial parameters including presence or absence of anti-P antibodies (23.1% vs. 20%, respectively, p =1.0), disease activity, as measured by the Systemic Lupus Erythematosus Disease activity Index (4.08±5.7 vs. 4.95±6.3 respectively, p =0.60) and cumulated damage, as measured by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (0.7±2.3 vs. 0.3±0.7 respectively, p =0.33). Conclusions: Mood and anxiety disorders are the most frequently observed psychiatric disorders in female SLE patients without concomitant neurological manifestations. These mild/moderate forms of psychiatric disorders are not associated with anti-P antibodies in SLE patients. Our findings reinforce the importance of systematic psychiatric evaluation for these patients in order to provide adequate and comprehensive care. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
4. Mycophenolate mofetil is effective in reducing lupus glomerulonephritis proteinuria.
- Author
-
Borba, Eduardo F., Guedes, Lissiane K., Christmann, Romy B., Figueiredo, Camille P., Gonçalves, Célio R., and Bonfá, Eloisa
- Subjects
- *
LUPUS nephritis , *KIDNEY diseases , *PROTEINURIA , *BIOPSY , *IMMUNOSUPPRESSIVE agents , *SERUM albumin , *PATIENTS - Abstract
Mycophenolate mofetil (MMF) significantly reduces proteinuria in experimental model of human membranous nephropathy (Heymann nephritis). Twenty consecutive SLE patients with persistent isolated severe proteinuria and/or proteinuric flare were studied for 18 months of MMF therapy. All of them presented stable renal function and 12 had biopsy proven membranous glomerulonephritis (WHO class V). The starting daily dose for MMF was 1.5 g to a maximum of 3 g. Patients were divided into: partial response, ≥50% decrease of baseline proteinuria; complete response, normal proteinuria levels (less than 0.3 g/24 h); flare, increase of at least 50% of the mean baseline proteinuria. All 20 SLE patients (100%) presented a 50% reduction of baseline proteinuria which was achieved in 8.2±3.3 months of MMF therapy, at a mean daily dose of 2.3±0.5 g. A significant decrease in 24-h protein excretion was observed compared to entry (3.47±1.26 vs. 1.33±0.67 g, P<0.0001) as well as a correspondent increase of serum albumin (3.2±0.4 vs. 3.7±0.4 mg/dl, P=0.02) and reduction of prednisone dose (33.7±20.0 to 18.6±14.1 mg/day, P=0.01). Complete response was observed in 11 SLE patients (55%) in 12.2±3.0 months of therapy with a significant decrease in proteinuria (P<0.0001), prednisone dose (P<0.0001) and an increase of serum albumin (P=0.003). Interestingly, initial proteinuria or serum albumin levels did not identify patients with complete response and those with partial response at the end of the study (P=0.543 and 0.657, respectively). Our pilot prospective study suggests that MMF appears to be effective in reducing severe persistent proteinuria in lupus glomerulonephritis, even in patients unresponsive to other immunosuppressive treatments. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
5. Mechanisms of dyslipoproteinemias in systemic lupus erythematosus.
- Author
-
Borba, Eduardo F., Carvalho, Jozelio F., and Bonfá, Eloísa
- Subjects
- *
DYSLIPIDEMIA , *SYSTEMIC lupus erythematosus , *HYPERLIPIDEMIA , *ATHEROSCLEROSIS treatment , *INFLAMMATION , *AUTOANTIBODIES , *HIGH density lipoproteins , *DIAGNOSIS , *THERAPEUTICS - Abstract
Autoimmunity and inflammation are associated with marked changes in lipid and lipoprotein metabolism in SLE. Autoantibodies and cytokines are able to modulate lipoprotein lipase (LPL) activity, a key enzyme in lipid metabolism, with a consequent “lupus pattern” of dyslipoproteinemia characterized by elevated levels of very low-density lipoprotein cholesterol (VLDL) and triglycerides (TG) and lower high-density lipoprotein cholesterol (HDL) levels. This pattern favors an enhanced LDL oxidation with a subsequent deleterious foam cell formation. Autoantibodies and immunocomplexes may aggravate this oxidative injury by inducing accumulation and deposition of oxLDL in endothelial cells. Drugs and associated diseases usually magnify the close interaction of these factors and further promote the proatherogenic environment of this disease. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
6. Lipoprotein profile in limited systemic sclerosis.
- Author
-
Borba, Eduardo F., Borges, Claudia T. L., and Bonfá, Eloísa
- Subjects
- *
LIPOPROTEINS , *ISOPENTENOIDS , *CHOLESTEROL , *PULMONARY hypertension , *MULTIPLE sclerosis , *HYPERTENSION - Abstract
The objective of this study was to determine the lipoprotein profile of limited cutaneous systemic sclerosis (LcSSc). Fasting lipids were determined in 24 female patients and 24 healthy age-matched and sex-matched controls. Exclusion criteria were conditions that induce an altered lipid profile. Lipoprotein levels of risk were determined in accordance with the National Cholesterol Education Program (NCEP). Significantly lower levels of high-density lipoprotein (HDL) cholesterol (47.6±12.4 mg dL−1 vs. 58.2±12.3 mg dL−1; P=0.003) and total cholesterol (197.0±40.7 mg dL−1 vs. 222.0±34.0 mg dL−1; P=0.02) were observed in LcSSc patients than in controls. The presence of anti-centromere antibodies (ACA) was also associated with lower HDL levels (45.0±12.1 mg dL−1) compared to ACA-negative patients and controls (50.2±12.6 and 58.2±12.3 mg dL−1, respectively, P=0.01). The only clinical variable associated with low HDL levels was pulmonary hypertension (PH) (33.6±2.3 mg dL−1 vs. 49.6±11.9 mg dL−1, P=0.01). No significant correlation was observed among HDL levels and ESR ( r=−0.313; P=0.14), CRP ( r=−0.296; P=0.16), or BMI ( r=−0.263; P=0.21). Remarkably, a higher percentage of risk HDL levels was identified in LcSSc patients (41.6%) than in healthy controls (8.3%) ( P=0.02). Our data suggest that LcSSc patients, particularly those who are ACA positive, have an adverse lipid profile characterized by low HDL levels, a known independent risk for CAD in women. The relevance of this finding for the development of atherosclerosis in this disease must be confirmed by epidemiological studies. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
7. Time to diagnosis in systemic lupus erythematosus: Associated factors and its impact on damage accrual and mortality. Data from a multi-ethnic, multinational Latin American lupus cohort.
- Author
-
Nieto, Romina, Quintana, Rosana, Zavala-Flores, Ernesto, Serrano, Rosa, Roberts, Karen, Catoggio, Luis J, García, Mercedes A, Berbotto, Guillermo A, Saurit, Verónica, Bonfa, Eloisa, Borba, Eduardo F, Lavras Costallat, Lilian T, Da Silva, Nilzio A, Sato, Emilia I, Tavares Brenol, Joao C, Massardo, Loreto, Neira, Oscar J, Vázquez, Gloria, Guibert Toledano, Marlene, and Pascual-Ramos, Virginia
- Subjects
- *
DELAYED diagnosis , *SYSTEMIC lupus erythematosus , *HEALTH insurance , *SYMPTOMS , *MORTALITY , *DIAGNOSIS - Abstract
Background: Systemic lupus erythematosus (SLE) often mimics symptoms of other diseases, and the interval between symptom onset and diagnosis may be long in some of these patients. Aims: To describe the characteristics associated with the time to SLE diagnosis and its impact on damage accrual and mortality in patients with SLE from a Latin American inception cohort. Methods: Patients were from a multi-ethnic, multi-national Latin-American SLE inception cohort. All participating centers had specialized lupus clinics. Socio-demographic, clinical/laboratory, disease activity, damage, and mortality between those with a longer and a shorter time to diagnosis were compared using descriptive statistical tests. Multivariable Cox regression models with damage accrual and mortality as the end points were performed, adjusting for age at SLE diagnosis, gender, ethnicity, level of education, and highest dose of prednisone for damage accrual, plus highest dose of prednisone, baseline SLEDAI, and baseline SDI for mortality. Results: Of the 1437 included in these analyses, the median time to diagnosis was 6.0 months (Q1–Q3 2.4–16.2); in 721 (50.2%) the time to diagnosis was longer than 6 months. Patients whose diagnosis took longer than 6 months were more frequently female, older at diagnosis, of Mestizo ethnicity, not having medical insurance, and having "non-classic" SLE symptoms. Longer time to diagnosis had no impact on either damage accrual (HR 1.09, 95% CI 0.93–1.28, p = 0.300) or mortality (HR 1.37, 95% CI 0.88–2.12, p = 0.200). Conclusions: In this inception cohort, a maximum time of 24 months with a median of 6 months to SLE diagnosis had no apparent negative impact on disease outcomes (damage accrual and mortality). [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Predictors of severe hemolytic anemia and its impact on major outcomes in systemic lupus erythematosus: Data from a multiethnic Latin American cohort.
- Author
-
González, Luis Alonso, Alarcón, Graciela S., Harvey, Guillermina B., Quintana, Rosana, Pons-Estel, Guillermo J., Ugarte-Gil, Manuel F., Vásquez, Gloria, Catoggio, Luis J., García, Mercedes A., Borba, Eduardo F., Da Silva, Nilzio A., Tavares Brenol, João C., Guibert Toledano, Marlene, Massardo, Loreto, Neira, Oscar, Pascual-Ramos, Virginia, Amigo, Mary-Carmen, Barile-Fabris, Leonor A., García De La Torre, Ignacio, and Alfaro-Lozano, José
- Subjects
- *
HEMOLYTIC anemia , *AUTOIMMUNE hemolytic anemia , *SYSTEMIC lupus erythematosus - Abstract
Objective: To determine the predictors of the occurrence of severe autoimmune hemolytic anemia (AIHA) and its impact on damage accrual and mortality in SLE patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Penile anthropometry in adolescents and adults systemic lupus erythematosus.
- Author
-
Vecchi, Ana P., Borba, Eduardo F., Bonfá, Eloísa, Cocuzza, Marcelo, Pieri, Patrícia, Kim, Chong A, and Silva, Clovis A.
- Subjects
- *
SYSTEMIC lupus erythematosus - Abstract
An abstract of the conference paper "Penile anthropometry in adolescents and adults systemic lupus erythematosus," by Ana P. Vecchi, and colleagues, is presented.
- Published
- 2011
- Full Text
- View/download PDF
10. Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome.
- Author
-
Signorelli, Flavio, Balbi, Gustavo Guimarães Moreira, Aikawa, Nadia E, Silva, Clovis A, Kupa, Léonard de Vinci Kanda, Medeiros-Ribeiro, Ana C, Yuki, Emily FN, Pasoto, Sandra G, Saad, Carla GS, Borba, Eduardo F, Seguro, Luciana Parente Costa, Pedrosa, Tatiana, Oliveira, Vitor Antonio de Angeli, Costa, Ana Luisa Cerqueira de Sant'Ana, Ribeiro, Carolina T, Santos, Roseli Eliana Beseggio, Andrade, Danieli Castro Oliveira, and Bonfá, Eloisa
- Subjects
- *
COVID-19 vaccines , *PHOSPHOLIPID antibodies , *COVID-19 , *IMMUNE response , *ANTIPHOSPHOLIPID syndrome - Abstract
Objective: Coronavirus disease 19 (COVID-19) has an increased risk of coagulopathy with high frequency of antiphospholipid antibodies (aPL). Recent reports of thrombosis associated with adenovirus-based vaccines raised concern that SARS-CoV-2 immunization in primary antiphospholipid syndrome (PAPS) patients may trigger clotting complications. Our objectives were to assess immunogenicity, safety, and aPL production in PAPS patients, after vaccinating with Sinovac-CoronaVac, an inactivated virus vaccine against COVID-19. Methods: This prospective controlled phase-4 study of PAPS patients and a control group (CG) consisted of a two-dose Sinovac-CoronaVac (D0/D28) and blood collection before vaccination (D0), at D28 and 6 weeks after second dose (D69) for immunogenicity/aPL levels. Outcomes were seroconversion (SC) rates of anti-SARS-CoV-2 S1/S2 IgG and/or neutralizing antibodies (NAb) at D28/D69 in naïve participants. Safety and aPL production were also assessed. Results: We included 44 PAPS patients (31 naïve) and 132 CG (108 naïve) with comparable age (p =0.982) and sex (p >0.999). At D69, both groups had high and comparable SC (83.9% vs. 93.5%, p =0.092), as well as NAb positivity (77.4% vs. 78.7%, p =0.440), and NAb-activity (64.3% vs. 60.9%, p =0.689). Thrombotic events up to 6 months or other moderate/severe side effects were not observed. PAPS patients remained with stable aPL levels throughout the study at D0 vs. D28 vs. D69: anticardiolipin (aCL) IgG (p =0.058) and IgM (p =0.091); anti-beta-2 glycoprotein I (aβ2GPI) IgG (p =0.513) and IgM (p =0.468). Conclusion: We provided novel evidence that Sinovac-CoronaVac has high immunogenicity and safety profile in PAPS. Furthermore, Sinovac-CoronaVac did not trigger thrombosis nor induced changes in aPL production. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. Hydroxychloroquine increased cholesterol transfer to high-density lipoprotein in systemic lupus erythematosus: A possible mechanism for the reversal of atherosclerosis in the disease.
- Author
-
Lang, Maria G, Vinagre, Carmen GC, Bonfa, Eloisa, Freitas, Fatima R, Pasoto, Sandra G, Brito, Tatiane S, Seguro, Luciana PC, Maranhão, Raul C, and Borba, Eduardo F
- Subjects
- *
HDL cholesterol , *SYSTEMIC lupus erythematosus , *BLOOD lipids , *HYDROXYCHLOROQUINE , *BODY mass index , *ATHEROSCLEROSIS - Abstract
Introduction: The beneficial effect of hydroxychloroquine (HCQ) in decreasing LDL levels on Systemic Lupus Erythematosus (SLE) is well defined. The influence of this drug on HDL levels is still under debate and information about its effect on cholesterol reverse transport is lacking. Objective: To evaluate the effects of HCQ on HDL levels and the transfer of lipids to this lipoprotein in SLE. Methods: Nineteen SLE patients using only HCQ (SLE WITH HCQ), 19 SLE patients without any therapy (SLE WITHOUT THERAPY), and 19 healthy controls (CONTROL) were included. All three groups were premenopausal women age- and gender-matched. Serum lipids and apolipoproteins were determined by commercial kits. An in vitro transfer of four lipids (14C-Phospolipid, 3H-Cholesteryl ester, 3H-Triglyceride, and 14C-Unesterified cholesterol) from a radioactively labeled nanoemulsion donor to HDL was performed in all participants. Results: Groups had comparable mean age, weight, height, BMI(body mass index), and waist circumference (p >.05). Mean HDL levels were higher in SLE WITH HCQ group compared to SLE WITHOUT THERAPY(58.37 ± 14.04 vs 49.79 ± 8.0 mg/dL; p <.05) but lower than CONTROL (58.37 ± 14.04 vs 68.58 ± 9.99 mg/dL; p <.05). Total cholesterol (TC) and LDL levels were also significantly lower in SLE WITH HCQ compared SLE WITHOUT THERAPY(148.16 ± 16.43 vs 167.11 ± 30.18 mg/dL; p <.05, 75.05 ± 22.52 vs 96.05 ± 25.63 mg/dL; p <.05) and CONTROL (148.16 ± 16.43 vs 174.11 ± 23.70 mg/dL; p <.05, 75.05 ± 22.52 vs 88.53 ± 20.24 mg/dL; p <.05). The in vitro lipid transfer to HDL study revealed a significant difference among the three groups (p =.002) with a higher transfer of unesterified cholesterol(UC) in SLE WITH HCQ compared to SLE WITHOUT THERAPY(5.40 ± 1.05% vs. 4.44 ± 1.05%; p <.05). The latter was significantly decreased compared to CONTROL (5.40 ± 1.05% vs. 5.99 ± 1.71%; p <.05).The percentages of transfer of triacylglycerol (4.93 ± 0.69% vs. 4.50 ± 0.69% vs. 5.14 ± 1.01%; p =.054), esterified cholesterol (5.24 ± 0.70% vs. 4.96 ± 0.89% vs. 5.69 ± 1.27%; p =.079), and phospholipid (15.67 ± 1.03% vs. 15.34 ± 1.44% vs. 16.47 ± 1.89%; p =.066) were similar among groups. Conclusion: The present study is the first to demonstrate that HCQ promoted a higher transfer of unesterified cholesterol which may account for the increased HDL levels in lupus patients under HCQ. This desirable effect may underlie the reported reduced atherosclerosis in SLE. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
12. 2019-EULAR/ACR classification criteria domains at diagnosis: predictive factors of long-term damage in systemic lupus erythematosus.
- Author
-
Insfrán, Carlos E., Aikawa, Nadia E., Pasoto, Sandra G., Filho, Dilson M. N., Formiga, Francisco F. C., Pitta, Ana C., Borba, Eduardo F., Ribeiro, Carolina T., Silva, Clovis A., and Bonfa, Eloisa
- Subjects
- *
SYSTEMIC lupus erythematosus , *PHOSPHOLIPID antibodies , *LOGISTIC regression analysis , *DISEASE duration - Abstract
The objective of this study is to assess the role of the 2019-European League Against Rheumatism/American College of Rheumatology (2019-EULAR/ACR) classification criteria at diagnosis and its domains in predicting long-term damage in systemic lupus erythematosus(SLE). We performed a retrospective analysis using an electronic chart database utilized in routine clinical care of SLE patients and established in 2000 in a tertiary hospital. Two hundred and nine consecutive SLE patients with disease onset ≥18 years old and long disease duration were included. Cumulative damage at the last visit was scored using the SLICC/ACR-Damage Index (SDI). The median age at SLE diagnosis was 28 years (18–63), disease duration was 14 years (8–25), and 88% were females. Damage (SDI≥1) was observed in 116/209 (55%). Patients with (SDI≥1, n=116) and without damage (SDI=0, n=93) had similar median disease duration [14 (8–25) vs. 12 (8–25) years, p=0.090] and age at diagnosis [23 (18–55) vs. 23 (18–56) years, p=0.998]. No correlation was observed between total 2019-EULAR/ACR score at diagnosis and SDI at last visit (r=0.007, p=0.913). Presence of renal domain at diagnosis was associated with renal damage at last visit (OR=3.6, 95%CI 1.2–10.4, p=0.017) and antiphospholipid antibodies domain predicted neuropsychiatric damage (OR=3.0, 95%CI 1.2–7.6, p=0.015). A ROC analysis identified that a cut-off >24 in 2019-EULAR/ACR score could predict a trend for renal damage (p=0.077) with a lower renal survival (Kaplan-Meier curve) for patients above this limit (p=0.029). A multivariate logistic regression analysis revealed that 2019-EULAR/ACR score >24 at diagnosis (OR 4.583, 95%CI 1.052–19.962, p=0.043) was independently associated with renal damage. Specific domains in the 2019-EULAR/ACR criteria at diagnosis were associated with long-term organ-specific damage, particularly renal and neuropsychiatric harm. A 2019-EULAR/ACR score >24 predicted worse renal survival. Key Points • Presence of renal domain of the 2019-EULAR/ACR classification criteria at diagnosis was associated with long-term renal damage. • Presence of antiphospholipid antibodies domain at diagnosis was associated with long-term neuropsychiatric damage. • A 2019-EULAR/ACR overall score >24 at diagnosis was independently associated with renal damage and predicted worse renal long-term survival. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. Avoiding misclassification of thrombotic primary antiphospholipid syndrome as systemic lupus erythematosus (SLE): What are the best-performing SLE classification criteria?
- Author
-
Signorelli, Flavio, Balbi, Gustavo Guimarães Moreira, Bonfá, Eloisa, Borba, Eduardo F, and Andrade, Danieli Castro de Oliveira
- Subjects
- *
SYSTEMIC lupus erythematosus , *ANTIPHOSPHOLIPID syndrome - Abstract
Background: Systemic lupus erythematosus (SLE) and Primary Antiphospholipid Syndrome (PAPS) overlap clinical and immunological features. Therefore, misclassification of PAPS patients as SLE is a concern. The ACR/EULAR 2019 SLE classification has never been studied in PAPS. Objective: To verify if the ACR/EULAR 2019 SLE classification can correctly classify a PAPS patient as not having SLE and compare its performance with the SLICC 2012 SLE classification. Methods: One-hundred thrombotic PAPS patients who fulfilled the Sidney criteria were consecutively screened and those who attended the inclusion criteria were submitted to ACR/EULAR 2019 and SLICC 2012 classifications. Results: Sixty-seven PAPS patients were included in this study. The majority was female (89.6%) with median age at study inclusion of 45 years (35–53) and median PAPS disease duration of 13 years (8–19). PAPS correct classification was observed more often with ACR/EULAR 2019 than SLICC 2021 criteria (94.0% vs. 64.2%; p < 0.001). The 4 misclassified patients in ACR/EULAR 2019 were also misclassified in SLICC 2012. The comparison of misclassified patients to those correctly not classified as SLE resulted, for both criteria, in higher frequencies of hematological domain [ACR/EULAR 2019 (100% vs. 28.6%, p = 0.010) and SLICC 2012 (95.8% vs. 11.6%, p < 0.001)]. Further analysis of hematological manifestations revealed that for the ACR/EULAR 2019 leukopenia (100% vs. 22.2%, p = 0.004) and for the SLICC 2012 leukopenia/lymphopenia (91.7% vs. 7%, p < 0.001) were more frequent in misclassified group. Proteinuria (20.8% vs. 0%, p = 0.004) and low complement (45.8% vs. 20.9%, p = 0.033) were also more often observed in the incorrectly SLICC 2012 classified patients. Conclusion: ACR/EULAR 2019 had high accuracy for distinguishing PAPS from SLE, whereas the SLICC 2012 incorrectly classified more than one third of the PAPS patients as having SLE. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
14. Adrenal steroidogenesis and ovarian reserve in adult childhood-onset systemic lupus erytematosus patients.
- Author
-
Lourenço, Daniela M. R., Araújo, Daniel B., Aikawa, Nadia E., Yamakami, Lucas Y. S., Borba, Eduardo F., Maciel, Gustavo A. R., Soares-Junior, Jose M., Baracat, Edmund C., Pereira, Rosa M. R., Bonfa, Eloisa, and Silva, Clovis A.
- Subjects
- *
OVARIAN reserve , *ADULTS , *SYSTEMIC lupus erythematosus , *ANTI-Mullerian hormone , *OVARIAN cancer , *HYDROCORTISONE - Abstract
Objective: To assess overall adrenal mineralocorticoid/glucocorticoid/androgen steroidogenesis in childhood-onset systemic lupus erythematosus (cSLE) patients and the possible effect of prednisone on adrenal hormones and ovarian reserve. Methods: Fifty-one adult cSLE (ACR criteria) patients and 23 healthy controls were evaluated for adrenal steroidogenesis including mineralocorticoid (progesterone, deoxycorticosterone, aldosterone), glucocorticoid (17-OHprogesterone, 11-desoxycortisol, cortisol), and androgen (dehydroepiandrosterone-sulfate, androstenedione, total testosterone, and dihydrotestosterone) hormones. Ovarian reserve assessment included follicle-stimulating hormone (FSH), estradiol, anti-Müllerian hormone, ovarian volumes, and antral follicle count. Results: The median of current age [29.11 (19–39.8) vs. 30.8 (19.6–42.1) years, p = 0.502] was similar in adult cSLE and controls. Regarding mineralocorticoid/glucocorticoid, the median of progesterone (p = 0.003), 17-OH progesterone (p < 0.001), and 11-desoxycortisol (p = 0.036) were significantly lower in patients compared to controls. All androgen steroidogenesis hormones were reduced in the former group [dehydroepiandrosterone-sulfate (p < 0.001), androstenedione (p = 0.001), total testosterone (p = 0.005), and dihydrotestosterone (p < 0.001)]. Further comparison of patients with and without current use of prednisone and controls revealed a predominant impact on adrenal glucocorticoid and androgen steroidogenesis with reduced levels of 17-OH progesterone [0.17 (0–0.5) vs. 0.27 (0.1–2.9) vs. 0.33 (0.1–0.8) ng/mL, p < 0.001], dehydroepiandrosterone-sulfate [0.155 (0–0.6) vs. 0.49 (0.1–1.6) vs. 1.11 (0.1–2.6) μg/mL, p < 0.001], androstenedione [0.56 (0.2–4.4) vs. 1.7 (0.5–4.5) vs. 2.33 (0.3–3.8) ng/mL, p < 0.001], total testosterone [12 (12–167) vs. 16 (12–28) vs. (16.5 (0–50) ng/d, p = 0.002], and dihydrotestosterone [92.68 (11.8–198.5) vs. 160.62 (37.9–842.1) vs. 188.3 (71.3–543.9) pg/ml, p < 0.001] in patients under this drug. In addition, patients with this therapy had reduced median ovarian volumes [4.14 (2–12) vs. 7.13 (2–25.7) vs. 5.18 (2.4–17.3) cm3, p = 0.028) that was not associated with cyclophosphamide cumulative dose (p > 0.05). The median prednisone dose was 15/mg/day (2.5–40). Conclusions: We provided novel evidence that cSLE patients have an overall androgen/glucocorticoid/mineralocorticoid adrenal suppression. Furthermore, low/moderate prednisone use seems to underlie these abnormalities and may also adversely affect ovarian reserve, independently of immunosuppressants. Key Points • cSLE patients have an overall androgen/glucocorticoid/mineralocorticoid adrenal suppression. • Low/moderate prednisone use may affect ovarian reserve, independently of immunosuppressants. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
15. Factors associated with neuropsychiatric involvement in Latin American patients with systemic lupus erythematosus.
- Author
-
Barile-Fabris, Leonor A, Fragoso-Loyo, Hilda, Wojdyla, Daniel, Quintana, Rosana, Pons-Estel, Guillermo J, Catoggio, Luis J, García, Mercedes A, Saurit, Verónica, Drenkard, Cristina, Bonfa, Eloisa, Borba, Eduardo F, Sato, Emilia, Tavares Brenol, Joao C, Cavalcanti, Fernando, Da Silva, Nilzio A, Lavras Costallat, Lilian T, Guibert Toledano, Marlene, Massardo, Loreto, Neira, Oscar, and Cardiel, Mario H
- Subjects
- *
LATIN Americans , *SYSTEMIC lupus erythematosus , *HEMOLYTIC anemia , *PROGNOSIS , *DISEASE duration , *DISEASE progression - Abstract
Introduction: Factors related to presentation of neuropsychiatric (NP) SLE manifestations, early in the course of the disease, and during follow up have not been clearly established. Purpose: To identify disease and non-disease related factors associated with NP manifestations in early SLE. Methods: We included 1193 patients from the GLADEL inception cohort free of NP involvement at cohort entry. We evaluated the association of demographic, clinical and laboratory data with NP involvement during follow-up. Statistical methods: Independent factors associated with NP involvement were identified using a multivariable Cox regression model. Results: Factors independently associated with NP manifestations were: mestizo ethnicity (HR 1.701, 95% CI 1.282–2.258, p = 0.0002), myalgias/myositis (HR 1.832, 95% CI 1.335–2.515, p = 0.0002), pneumonitis (HR 2.476, 95% CI 1.085–5.648, p = 0.0312), shrinking lung (HR 2.428, 95% CI 1.074–5.493, p = 0.0331) and hemolytic anemia (HR 1.629, 95% CI 1.130–2.347, p = 0.0089). Longer disease duration at cohort entry (13 to 24 months) was associated with a lower risk of developing NP manifestations (HR 0.642, 95% CI 0.441–0.934, p = 0.0206). Conclusions: Patients with myalgias/myositis, pneumonitis, shrinking lung and hemolytic anemia are at higher risk of NP involvement, whereas longer disease duration at cohort entry is associated with a lower risk of developing NP involvement. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
16. Hydroxychloroquine blood levels in stable lupus nephritis under low dose (2–3 mg/kg/day): 12-month prospective randomized controlled trial.
- Author
-
Zanetti, Caio B., Pedrosa, Tatiana, Kupa, Léonard de V. K., Aikawa, Nadia E., Borba, Eduardo F., Vendramini, Margarete B. G., Silva, Clovis A., Pasoto, Sandra G., and Bonfa, Eloisa
- Subjects
- *
LUPUS nephritis , *LIQUID chromatography-mass spectrometry , *RANDOMIZED controlled trials , *HYDROXYCHLOROQUINE , *SYSTEMIC lupus erythematosus - Abstract
Introduction: The American Academy of Ophthalmology (2016-AAO) recommended hydroxychloroquine (HCQ) dose not to exceed 5 mg/kg/day (real body weight). Recently, it was reported that prescribed 2016-AAO dose provided adequate HCQ levels for most lupus nephritis (LN) patients, with low flare risk. However, the minimum HCQ dose required to keep adequate levels is unknown. Objectives: To evaluate if a further reduction in 2016-AAO dose (2–3 mg/kg/day) would sustain 12-month HCQ levels in LN patients with stable inactive disease. Methods: Seventy-three stable LN patients under prescribed full HCQ 2016-AAO dose for ≥6 months and adequate baseline HCQ levels (≥613.5 ng/mL) were divided in two groups: reduced 2016-AAO dose (2–3 mg/kg/day), n = 32, and full 2016-AAO dose (5 mg/kg/day), n = 41. All patients were assessed at baseline, 3, 6, and 12 months. HCQ levels were measured by liquid chromatography-tandem mass spectrometry. Flare was defined as augment ≥ 3 in SLE Disease Activity Index-2000 and/or change in treatment. Rigorous clinical/laboratorial surveillance was performed. Results: Prospective evaluation revealed for reduced 2016-AAO dose group a decrease of HCQ levels from baseline to 3 months (1,404.9 ± 492.0 vs. 731.6 ± 385.0 ng/mL, p < 0.01), and sustained levels at 6 months (p = 0.273) and 12 months (p = 0.091) compared to 3 months. For the full 2016-AAO dose group, a decrease occurred only from baseline to 12 months (1343.5 ± 521.5 vs. 991.6 ± 576.3 ng/mL, p < 0.001). Frequencies of patients with inadequate levels at 6 months was higher in reduced 2016-AAO group than full 2016-AAO dose (59% vs. 24%, p = 0.005), as well as at 12 months (66% vs. 32%, p = 0.002). Six-month and 12-month flare frequencies were comparable for both groups (p > 0.05). Conclusions: Prescribed HCQ low-dose regimen (2–3 mg/kg/day) does not sustain, for most patients, 6- and 12-month adequate HCQ levels. Full 2016-AAO dose maintained HCQ levels way above this limit. Trail registration: ClinicalTrials.gov: NCT03122431, registered on April 20, 2017 Key Points • Reduced American Academy of Ophthalmology (2016-AAO) hydroxychloroquine (HCQ) dose (2–3 mg/kg/day, real body weight) is unable to sustain HCQ blood levels within the safe cut-off defined for flare risk. • Full 2016-AAO dose (5 mg/kg/day) maintains a safe pattern of HCQ levels up to 12 months. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
17. Understanding the dynamics of hydroxychloroquine blood levels in lupus nephritis.
- Author
-
Pedrosa, Tatiana N, Pasoto, Sandra G, Aikawa, Nadia E, Yuki, Emily FN, Borba, Eduardo F, Filho, Julio CR Ferreira, Carricondo, Pedro C, Zanetti, Caio B, Conde, Paola G, Duarte, Nilo JC, Fontoura, Nicole, Romano, Paschoalina, Carvalho, Valdemir M, Silva, Clovis A, and Bonfa, Eloisa
- Subjects
- *
LUPUS nephritis , *LIQUID chromatography-mass spectrometry , *HYDROXYCHLOROQUINE , *SYSTEMIC lupus erythematosus - Abstract
Objectives: It is unknown if hydroxychloroquine blood level dynamics impact flare rates in lupus nephritis patients. We prospectively evaluated hydroxychloroquine levels to determine which blood-based patterns are more associated with disease activity. Methods: In total, 82 lupus nephritis patients under a prescribed hydroxychloroquine dose of 4–5.5 mg/kg actual body weight (maximum 400 mg/day) for ≥3 months were evaluated at baseline and 7 months. Hydroxychloroquine blood levels were determined by liquid chromatography-tandem mass spectrometry. Flare was defined as increase ≥3 in the Systemic Lupus Erythematosus Disease Activity Index 2000 score and/or a change or increase in therapy. Results: Overall, 9/82(11%) patients had flares during follow-up and had lower baseline hydroxychloroquine blood levels than those without flares (220.4 (53.5–1471.1) vs. 1006.3 (53.5–2137.8) ng/ml, p = 0.013). The hydroxychloroquine blood level cut-off that best predicted flares was 613.5 ng/ml (odds ratio = 8.67, 95% confidence interval: 1.66–45.18, p = 0.006). For 77 (94%) patients, the 7-month hydroxychloroquine level dynamics was evaluated and revealed: 59/77 (77%) had a persistent pattern of adequate (41/77(53%)) or fluctuating (18/77 (23%)) levels, with a low and comparable risk of flares (2/41 (5%) vs. 1/18 (5%), p = 1.000). The remaining group had persistent low levels (18/77 (23%)) and their flare frequency was significantly higher than the adequate group (5/18 (28%) vs. 2/41 (5%), p = 0.023). The frequencies of adequate/inadequate hydroxychloroquine blood levels in patients were comparable at baseline and 7 months (McNemar's test, p = 0.480). Conclusion: We provide novel evidence that hydroxychloroquine blood-level patterns (persistently low, adequate, or intermittent) have distinct impacts on flare rates in lupus nephritis patients. These findings reinforce the need of routine hydroxychloroquine measurements to maintain the appropriate blood levels. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
18. Establishing Surrogate Kidney End Points for Lupus Nephritis Clinical Trials: Development and Validation of a Novel Approach to Predict Future Kidney Outcomes.
- Author
-
Mackay, Meggan, Dall'Era, Maria, Fishbein, Joanna, Kalunian, Kenneth, Lesser, Martin, Sanchez‐Guerrero, Jorge, Levy, Deborah M., Silverman, Earl, Petri, Michelle, Arriens, Cristina, Lewis, Edmund J., Korbet, Stephen M., Conti, Fabrizio, Tesar, Vladimir, Hruskova, Zdenka, Borba, Eduardo F., Bonfa, Eloisa, Chan, Tak Mao, Rathi, Manish, and Gupta, K. L.
- Subjects
- *
LUPUS nephritis , *ACUTE kidney failure , *BIOMARKERS , *CHRONIC kidney failure , *CLINICAL trials , *CREATININE , *DATABASES , *MEDICAL information storage & retrieval systems , *KIDNEY diseases , *LONGITUDINAL method , *PROTEINURIA , *RACE , *RISK assessment , *THERAPEUTICS , *PROPORTIONAL hazards models , *SEVERITY of illness index , *DISEASE progression , *DIAGNOSIS - Abstract
Objective: End points currently used in lupus nephritis (LN) clinical trials lack uniformity and questionably reflect long‐term kidney survival. This study was undertaken to identify short‐term end points that predict long‐term kidney outcomes for use in clinical trials. Methods: A database of 944 patients with LN was assembled from 3 clinical trials and 12 longitudinal cohorts. Variables from the first 12 months of treatment after diagnosis of active LN (prediction period) were assessed as potential predictors of long‐term outcomes in a 36‐month follow‐up period. The long‐term outcomes examined were new or progressive chronic kidney disease (CKD), severe kidney injury (SKI), and the need for permanent renal replacement therapy (RRT). To predict the risk for each outcome, hazard index tools (HITs) were derived using multivariable analysis with Cox proportional hazards regression. Results: Among 550 eligible subjects, 54 CKD, 55 SKI, and 22 RRT events occurred. Variables in the final CKD HIT were prediction‐period CKD status, 12‐month proteinuria, and 12‐month serum creatinine level. The SKI HIT variables included prediction‐period CKD status, International Society of Nephrology (ISN)/Renal Pathology Society (RPS) class, 12‐month proteinuria, 12‐month serum creatinine level, race, and an interaction between ISN/RPS class and 12‐month proteinuria. The RRT HIT included age at diagnosis, 12‐month proteinuria, and 12‐month serum creatinine level. Each HIT validated well internally (c‐indices 0.84–0.92) and in an independent LN cohort (c‐indices 0.89–0.92). Conclusion: HITs, derived from short‐term kidney responses to treatment, correlate with long‐term kidney outcomes, and now must be validated as surrogate end points for LN clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
19. Circulating Follicular Helper-Like T Cells in Systemic Lupus Erythematosus: Association With Disease Activity.
- Author
-
Choi, Jin‐Young, Ho, John Hsi‐en, Pasoto, Sandra G., Bunin, Viviane, Kim, Sang Taek, Carrasco, Solange, Borba, Eduardo F., Gonçalves, Celio R., Costa, Priscila R., Kallas, Esper G., Bonfa, Eloisa, and Craft, Joseph
- Subjects
- *
SYSTEMIC lupus erythematosus , *ACADEMIC medical centers , *ANALYSIS of variance , *STATISTICAL correlation , *RESEARCH funding , *STATISTICS , *T cells , *T-test (Statistics) , *DATA analysis , *SEVERITY of illness index , *DATA analysis software , *PROGNOSIS - Abstract
Objective To assess circulating follicular helper T (Tfh)-like CD4+ T cells in patients with systemic lupus erythematosus (SLE) and determine their relationship to disease activity. Methods Blood samples from patients with SLE, as well as blood samples from patients with Behçet's disease (BD) and healthy individuals as controls, were analyzed. In all samples, circulating Tfh-like cells were enumerated by flow cytometry, using, as markers, expression of CXCR5, inducible T cell costimulator (ICOS), and programmed death 1 (PD-1) protein, as well as secretion of interleukin-21 (IL-21). The frequency of circulating Tfh-like cells was compared to that of circulating plasmablasts (CD19+IgD−CD38+). In addition, the possible association of circulating Tfh-like cells with the SLE Disease Activity Index (SLEDAI) was evaluated. Results The subset of circulating Tfh-like T cells, identified as CXCR5highICOShighPD-1high, was expanded in the blood of SLE patients compared to controls. Circulating Tfh-like cells were found to produce IL-21 and had lower expression of CCR7 as compared to that in circulating CXCR5high central memory T cells, thereby enabling their distinction. Expression of PD-1, but not ICOS or CXCR5, was significantly elevated in circulating Tfh-like cells from SLE patients compared to controls. PD-1 expression among CXCR5high circulating Tfh-like cells correlated with the SLEDAI, frequency of circulating plasmablasts, and anti-double-stranded DNA antibody positivity, but not with disease duration or past organ injury; rather, this cell profile appeared to be a reflection of current active disease. Conclusion Circulating Tfh-like cells are associated with disease activity in SLE, suggesting that their presence indicates abnormal homeostasis of T cell-B cell collaboration, with a causal relationship that is central to disease pathogenesis. These findings also suggest that circulating Tfh-like cells provide a surrogate for aberrant germinal center activity in SLE, and that their PD-1 expression offers a tool for measuring disease activity and monitoring the response to therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
20. Primary cardiac disease in systemic lupus erythematosus patients: protective and risk factors—data from a multi-ethnic Latin American cohort.
- Author
-
García, Mercedes A., Alarcón, Graciela S., Boggio, Gabriela, Hachuel, Leticia, Marcos, Ana Inés, Marcos, Juan Carlos, Gentiletti, Silvana, Caeiro, Francisco, Sato, Emilia I., Borba, Eduardo F., Brenol, João C. Tavares, Massardo, Loreto, Molina-Restrepo, José Fernando, Vásquez, Gloria, Guibert-Toledano, Marlene, Barile-Fabris, Leonor, Amigo, Mary-Carmen, Huerta-Yáñez, Guillermo F., Cucho-Venegas, Jorge M., and Chacón-Diaz, Rosa
- Published
- 2014
- Full Text
- View/download PDF
21. Primary cardiac disease in systemic lupus erythematosus patients: protective and risk factors—data from a multi-ethnic Latin American cohort.
- Author
-
García, Mercedes A., Alarcón, Graciela S., Boggio, Gabriela, Hachuel, Leticia, Marcos, Ana Inés, Marcos, Juan Carlos, Gentiletti, Silvana, Caeiro, Francisco, Sato, Emilia I., Borba, Eduardo F., Brenol, João C. Tavares, Massardo, Loreto, Molina-Restrepo, José Fernando, Vásquez, Gloria, Guibert-Toledano, Marlene, Barile-Fabris, Leonor, Amigo, Mary-Carmen, Huerta-Yáñez, Guillermo F., Cucho-Venegas, Jorge M., and Chacón-Diaz, Rosa
- Subjects
- *
PREVENTION of heart diseases , *HEART disease risk factors , *ANTIMALARIALS , *ACADEMIC medical centers , *CONFIDENCE intervals , *MORTALITY , *MULTIVARIATE analysis , *PERICARDITIS , *SURVIVAL , *SYSTEMIC lupus erythematosus , *LOGISTIC regression analysis , *PROPORTIONAL hazards models , *DATA analysis software , *DESCRIPTIVE statistics , *ODDS ratio , *DISEASE complications , *THERAPEUTICS - Abstract
Objectives. The aim of this study was to assess the cumulative incidence, risk and protective factors and impact on mortality of primary cardiac disease in SLE patients (disease duration ≤2 years) from a multi-ethnic, international, longitudinal inception cohort (34 centres, 9 Latin American countries).Methods. Risk and protective factors of primary cardiac disease (pericarditis, myocarditis, endocarditis, arrhythmias and/or valvular abnormalities) were evaluated.Results. Of 1437 patients, 202 (14.1%) developed one or more manifestations: 164 pericarditis, 35 valvulopathy, 23 arrhythmias, 7 myocarditis and 1 endocarditis at follow-up; 77 of these patients also had an episode of primary cardiac disease at or before recruitment. In the multivariable parsimonious model, African/Latin American ethnicity [odds ratio (OR) 1.80, 95% CI 1.13, 2.86], primary cardiac disease at or before recruitment (OR 6.56, 95% CI 4.56, 9.43) and first SLICC/ACR Damage Index for SLE assessment (OR 1.31, 95% CI 1.14, 1.50) were risk factors for the subsequent occurrence of primary cardiac disease. CNS involvement (OR 0.44, 95% CI 0.25, 0.75) and antimalarial treatment (OR 0.62, 95% CI 0.44, 0.89) at or before recruitment were negatively associated with the occurrence of primary cardiac disease risk. Primary cardiac disease was not independently associated with mortality.Conclusion. Primary cardiac disease occurred in 14.1% of SLE patients of the Grupo Latino Americano de Estudio de Lupus cohort and pericarditis was its most frequent manifestation. African origin and lupus damage were found to be risk factors, while CNS involvement at or before recruitment and antimalarial treatment were protective. Primary cardiac disease had no impact on mortality. [ABSTRACT FROM PUBLISHER]
- Published
- 2014
22. Anti-ribosomal P protein: a novel antibody in autoimmune hepatitis.
- Author
-
Calich, Ana L., Viana, Vilma S. T., Cancado, Eduardo, Tustumi, Francisco, Terrabuio, Débora R. B., Leon, Elaine P., Silva, Clovis A., Borba, Eduardo F., and Bonfa, Eloisa
- Subjects
- *
CHRONIC active hepatitis , *AUTOIMMUNE disease diagnosis , *SYSTEMIC lupus erythematosus , *RIBOSOMAL proteins , *LIVER diseases , *DIAGNOSIS - Abstract
Background Autoantibodies to ribosomal P proteins (anti-rib P) are specific serological markers for systemic lupus erythematosus ( SLE) and are associated with liver involvement in this disease. The similarity in autoimmune background between autoimmune hepatitis ( AIH) and SLE-associated hepatitis raises the possibility that anti-rib P antibodies might also have relevance in AIH. Aims To evaluate the frequency and clinical significance of anti-rib P antibodies in a large AIH cohort. Methods Sera obtained at diagnosis of 96 AIH patients and of 82 healthy controls were tested for IgG anti-ribosomal P protein by ELISA. All of the sera were also screened for other lupus-specific autoantibodies, three patients with the presence of anti-ds DNA ( n = 1) and anti-Sm ( n = 2) were excluded. Results Moderate to high titres (>40 U) of anti-rib P antibody were found in 9.7% (9/93) of the AIH patients and none of the controls ( P = 0.003). At presentation, AIH patients with and without anti-rib P antibodies had similar demographic/clinical features, including the frequency of cirrhosis (44.4 vs. 28.5%, P = 0.44), hepatic laboratorial findings ( P > 0.05). Importantly, at the final observation (follow-up period 10.2 ± 4.9 years), the AIH patients with anti-rib P had a significantly higher frequency of cirrhosis compared with the negative group (100 vs. 60%, P = 0.04). Conclusion The novel demonstration of anti-rib P in AIH patients without clinical or laboratory evidence of SLE suggests a common underlying mechanism targeting the liver in these two diseases. In addition, this antibody appears to predict the patients with worse AIH prognoses. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
23. Antimalarial Treatment May Have a Time-Dependent Effect on Lupus Survival.
- Author
-
Shinjo, Samuel K., Bonfá, Eloísa, Wojdyla, Daniel, Borba, Eduardo F., Ramirez, Luis A., Scherbarth, Hugo R., Brenol, João C. Tavares, Chacón-Diaz, Rosa, Neira, Oscar J., Berbotto, Guillermo A., de la Torre, Ignacio Garcia, Acevedo-Vázquez, Eduardo M., Massardo, Loreto, Barile-Fabris, Leonor A., Caeiro, Francisco, Silveira, Luis H., Sato, Emilia I., Buliubasich, Sandra, Alarcón, Graciela S., and Pons-Estel, Bernardo A.
- Subjects
- *
ANTIMALARIALS , *SYSTEMIC lupus erythematosus treatment , *AUTOIMMUNE diseases , *SOCIOECONOMIC factors , *DEMOGRAPHIC characteristics - Abstract
The article discusses the benefits of antimalarial treatment among patients who have a medical history of systemic lupus erythematosus (SLE). It mentions several criteria to be considered including laboratory findings, socioeconomic and demographic characteristics of the patient. It states that antimalarial treatment should be recommended for patients with a history of SLE since protective effects have been noted.
- Published
- 2010
- Full Text
- View/download PDF
24. Effectiveness of Medial-Wedge Insole Treatment for Valgus Knee Osteoarthritis.
- Author
-
Rodrigues, Priscilla T., Ferreira, Ana F., Pereira, Rosa M. R., Bonfá, Eloísa, Borba, Eduardo F., and Fuller, Ricardo
- Subjects
- *
KNEE diseases , *OSTEOARTHRITIS , *JOINT diseases , *FOOTWEAR , *PAIN , *BODY movement - Abstract
The article discusses a study which aims to assess the efficacy of medial-wedge insoles in valgus knee osteoarthritis (OA). Results show that significant reductions were observed for pain on movement in women who wore medial insoles. The study found that the use of medial-wedge insoles was highly effective in reducing pain at rest and on movement, as well as promoted a functional improvement of valgus knee OA.
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.